Lentivector Iterations and Pre-Clinical Scale-Up/Toxicity Testing: Targeting Mobilized CD34+ Cells for Correction of Fabry Disease

Huang, Khan, Au, Barber, López-Vásquez, Prokopishyn, Boutin, Rothe, Rip, Abaoui, Nagree, Dworski, Schambach, Keating, West, Klassen, Turner, Sirrs, Rupar, Auray-Blais, Foley, Medin. Lentivector Iterations and Pre-Clinical Scale-Up/Toxicity Testing: Targeting Mobilized CD34+ Cells for Correction of Fabry Disease. Molecular Therapy: Methods & Clinical Development Vol. 5 June 2017. doi:  10.1016/j.omtm.2017.05.003

Phenotypic properties of transmitted founder HIV-1.

Parrish NF, Gao F, Li H, Giorgi EE, Barbian HJ, Parrish EH, Zajic L, et al. Phenotypic properties of transmitted founder HIV-1 [published online before print March 29, 2013]. PNAS April 23, 2013 vol. 110, no. 17 6626-6633 doi:10.1073/pnas.1304288110.